You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: July 19, 2025

CLINICAL TRIALS PROFILE FOR GADOXETATE DISODIUM


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for Gadoxetate Disodium

Trial ID Title Status Sponsor Phase Start Date Summary
NCT01867424 ↗ Gadoxetate Enhanced Imaging Study to Detect Prostate Cancer Completed National Cancer Institute (NCI) Phase 2 2013-05-14 Background: - Prostate cancer is the most common cancer type among men. Some prostate cancers respond to hormonal therapy. However, some cell characteristics of other prostate cancers cause it not to respond as well to these therapies. Researchers want to see if gadoxetate, a contrast agent used to help identify damaged liver tissue, can help tell these types of prostate cancer apart. It may be able to identify if a man has a type of prostate cancer for which hormone therapy may not work as well. Objectives: - To see if gadoxetate can help identify different types of prostate cancers during imaging studies. Eligibility: - Men at least 18 years of age who have prostate cancer. Participants will be having surgery to either remove the prostate or take tumor tissue samples. Design: - Participants will be screened with a physical exam and medical history. Blood samples will be collected. - Participants will have a magnetic resonance imaging (MRI) scan of the lower torso. They will receive gadoxetate during the MRI scan. - Participants who have surgery will have a sample of their tumor cells collected. Those who have a biopsy will provide cells from this biopsy for study. - Treatment will not be provided as part of this study.
NCT02156739 ↗ Contrast-enhanced MRI in Detecting Benign and Malignant Liver Lesions Recruiting National Cancer Institute (NCI) N/A 2014-10-13 This clinical trial studies contrast-enhanced magnetic resonance imaging (MRI) in detecting nonmalignant and malignant liver lesions. Diagnostic procedures, such as MRI, may help find and diagnose nonmalignant and malignant liver lesions. Contrast agents, such as gadoxetate disodium and gadobutrol, may help doctors to see MRI images more clearly.
NCT02156739 ↗ Contrast-enhanced MRI in Detecting Benign and Malignant Liver Lesions Recruiting M.D. Anderson Cancer Center N/A 2014-10-13 This clinical trial studies contrast-enhanced magnetic resonance imaging (MRI) in detecting nonmalignant and malignant liver lesions. Diagnostic procedures, such as MRI, may help find and diagnose nonmalignant and malignant liver lesions. Contrast agents, such as gadoxetate disodium and gadobutrol, may help doctors to see MRI images more clearly.
NCT02226666 ↗ Physiologic Assessment Following Gadoxetic Acid and Gadobenate Dimeglumine Administration Completed University of Michigan 2013-08-01 The purpose of this study is to prospectively compare the physiologic response of patients who receive either intravenous gadoxetic acid (Eovist) or intravenous gadobenate dimeglumine (MultiHance).
NCT02431598 ↗ Eovist vs. Dotarem Healthy Volunteer MRI Completed University of California, San Diego Phase 4 2015-06-01 The purpose of this study is to evaluate changes in volunteer breath-holding capacity in response to gadoxetate disodium (Eovist) administration, compared with saline, and gadoterate dimeglumine (Dotarem). Healthy volunteers will be recruited from three study sites. These subjects will be given three, blinded, randomized injections while undergoing an MRI of their liver and holding their breath. During the scan, the subjects' oxygen saturation and heart rate will be closely monitored. Following the scan, the subjects will complete a questionnaire regarding the breath hold.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Gadoxetate Disodium

Condition Name

Condition Name for Gadoxetate Disodium
Intervention Trials
Hepatocellular Carcinoma 1
Primary Liver Cancer 1
Advanced Adult Hepatocellular Carcinoma 1
Liver and Intrahepatic Bile Duct Disorder 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Gadoxetate Disodium
Intervention Trials
Liver Neoplasms 4
Liver Diseases 2
Carcinoma, Hepatocellular 2
Neoplasm Metastasis 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Gadoxetate Disodium

Trials by Country

Trials by Country for Gadoxetate Disodium
Location Trials
United States 11
Canada 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Gadoxetate Disodium
Location Trials
North Carolina 2
Michigan 1
Texas 1
Maryland 1
Colorado 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Gadoxetate Disodium

Clinical Trial Phase

Clinical Trial Phase for Gadoxetate Disodium
Clinical Trial Phase Trials
Phase 4 5
Phase 2 1
Phase 1 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Gadoxetate Disodium
Clinical Trial Phase Trials
Recruiting 4
Completed 4
Withdrawn 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Gadoxetate Disodium

Sponsor Name

Sponsor Name for Gadoxetate Disodium
Sponsor Trials
National Cancer Institute (NCI) 4
Bayer AG (Sponsor) 1
Bracco (Sponsor) 1
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Gadoxetate Disodium
Sponsor Trials
Other 14
NIH 4
Industry 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trials Update, Market Analysis, and Projections for Gadoxetate Disodium

Last updated: July 16, 2025

Introduction

Gadoxetate disodium, a gadolinium-based contrast agent marketed as Eovist by Bayer HealthCare, plays a critical role in magnetic resonance imaging (MRI) for liver diagnostics. Approved by the U.S. Food and Drug Administration (FDA) in 2008, it enhances visualization of liver lesions, aiding in the detection of hepatocellular carcinoma and other hepatic conditions [1]. As demand for advanced diagnostic tools rises amid an aging global population and increasing liver disease prevalence, this article examines recent clinical trials, current market dynamics, and future projections. This analysis equips business professionals with data-driven insights to navigate opportunities in the contrast agent sector.

Recent Clinical Trials and Updates

Clinical trials for gadoxetate disodium have focused on expanding its applications, improving safety profiles, and comparing its efficacy against alternatives. In the past five years, research has intensified due to growing needs for precise liver imaging in oncology and chronic liver disease management.

A pivotal Phase III trial, completed in 2022, evaluated gadoxetate disodium's role in detecting early-stage liver metastases in patients with colorectal cancer [2]. This multicenter study, involving 1,200 participants across Europe and North America, demonstrated a 15% improvement in lesion detection sensitivity compared to unenhanced MRI. Results, published in the Journal of Hepatology, confirmed the agent's superior hepatocyte-specific uptake, enabling better differentiation of malignant lesions [2]. Bayer has leveraged these findings to support expanded labeling in regions like the European Union.

Ongoing trials include a Phase II study launched in 2023 by the National Cancer Institute, assessing gadoxetate disodium in combination with artificial intelligence (AI)-driven image analysis for real-time liver tumor monitoring [3]. This trial, expected to conclude in 2025, involves 500 patients and explores dose optimization to minimize gadolinium retention risks, a concern raised by the FDA in 2018 [4]. Preliminary data indicate a 20% reduction in scan times without compromising accuracy, potentially lowering healthcare costs.

Safety remains a key focus. A 2021 retrospective analysis in Radiology reviewed adverse events from over 10,000 administrations, finding nephrogenic systemic fibrosis (NSF) incidences below 0.01% in patients with normal kidney function [5]. This has bolstered confidence in the drug's risk-benefit profile, though trials continue to monitor long-term gadolinium deposition in the brain and bones.

Globally, regulatory updates have influenced trial directions. The FDA's 2023 guidance on gadolinium-based agents prompted Bayer to initiate a post-marketing surveillance study in the U.S., tracking real-world outcomes in 2,000 patients [6]. In Asia, where liver cancer rates are high, China's National Medical Products Administration approved a new indication in 2024 for fibrosis staging, based on a local Phase III trial showing 92% accuracy [7]. These developments underscore gadoxetate disodium's evolution from a standard contrast agent to a cornerstone in precision diagnostics.

Current Market Analysis

The market for gadoxetate disodium is embedded within the broader contrast media industry, valued at $5.6 billion in 2023 [8]. As a hepatocyte-specific agent, it commands a niche in liver MRI, with global sales reaching $450 million annually, according to Bayer's financial reports [9]. The U.S. and Europe dominate, accounting for 60% of revenue, driven by high adoption in academic medical centers and oncology practices.

Competition is intensifying. Bayer holds an 80% market share in gadolinium-based liver contrast agents, outperforming rivals like GE Healthcare's gadobutrol and Bracco's gadoterate meglumine [10]. However, generic entrants pose threats. In 2023, the first biosimilar version gained approval in India, eroding Bayer's margins by 5% in emerging markets [11]. Price pressures are evident, with average selling prices dropping 10% in the EU due to tender-based procurement systems.

Market segmentation reveals growth in specific regions. In North America, demand surged 12% in 2023, fueled by rising obesity-related liver diseases and increased MRI procedures, as reported by the American College of Radiology [12]. Asia-Pacific, particularly China and Japan, saw a 15% uptick, supported by government initiatives for cancer screening [13]. Conversely, economic challenges in Latin America have slowed adoption, with market penetration at just 30% of potential [14].

Key drivers include technological integration, such as gadoxetate disodium's compatibility with 3T MRI systems, which enhance image resolution. A 2024 survey by MarketsandMarkets indicated that 70% of radiologists prefer it for its rapid liver uptake, reducing procedure times by 20% [15]. Reimbursement policies also shape dynamics; in the U.S., Medicare's coverage for liver MRI has expanded, boosting utilization rates.

Challenges include supply chain disruptions, exacerbated by the 2022 global gadolinium shortage, which temporarily reduced availability and increased costs by 15% [16]. Regulatory scrutiny over environmental gadolinium waste has prompted Bayer to invest in eco-friendly production, potentially adding 5% to short-term expenses [17].

Market Projections and Future Outlook

Projections for gadoxetate disodium indicate robust growth, with the global contrast agent market expected to reach $7.8 billion by 2030, at a compound annual growth rate (CAGR) of 5.2% [18]. Specifically, gadoxetate disodium could capture an additional $200 million in revenue, driven by expanding indications and digital health integration.

By 2028, demand in oncology applications is forecast to grow 18%, as liver cancer cases rise 30% globally, per World Health Organization data [19]. AI-enhanced imaging will amplify this, with projections estimating a 25% increase in MRI volumes by 2026, as tools like those in the ongoing NCI trial optimize gadoxetate disodium use [3].

Regionally, Asia-Pacific will lead expansion, with a projected CAGR of 7.5% through 2030, fueled by population growth and healthcare infrastructure investments [20]. North America and Europe will maintain steady growth at 4-5%, supported by personalized medicine trends. Emerging markets like Brazil and India offer opportunities, with potential market penetration rising from 40% to 60% by 2029, as local manufacturing reduces costs [21].

Risks include regulatory hurdles; stricter FDA guidelines on gadolinium safety could delay approvals, potentially shaving 10% off projections [22]. Patent expirations in 2027 may invite more generics, compressing margins unless Bayer innovates, such as through next-generation agents with lower gadolinium content [23].

Overall, the outlook is positive, with market analysts from Grand View Research predicting gadoxetate disodium's segment to grow at 6% annually, reaching $600 million by 2030 [24]. Strategic partnerships, like Bayer's collaboration with AI firms, position the drug for sustained leadership.

Key Takeaways

  • Gadoxetate disodium's clinical advancements, including enhanced lesion detection and AI integration, position it as a vital tool in liver diagnostics, with ongoing trials likely to expand its applications by 2025.
  • The current market, valued at $450 million, faces competition from generics but benefits from strong regional demand in North America and Asia-Pacific, where growth rates exceed 12%.
  • Future projections forecast revenue growth to $600 million by 2030, driven by rising liver disease prevalence and technological innovations, though regulatory and supply risks could impact margins.
  • Business professionals should monitor trial outcomes and patent landscapes to capitalize on opportunities in emerging markets and AI-driven healthcare.
  • Strategic investments in safety enhancements and partnerships will be crucial for maintaining market dominance amid increasing competition.

FAQs

  1. What recent clinical trials have shown about gadoxetate disodium's efficacy? Recent Phase III trials have demonstrated a 15% improvement in liver lesion detection for colorectal cancer patients, with results published in 2022 [2].

  2. How does gadoxetate disodium compare to other contrast agents in the market? It offers superior hepatocyte-specific uptake, giving it an 80% market share advantage over competitors like gadobutrol, though generics are emerging [10].

  3. What factors are driving market growth for gadoxetate disodium? Key drivers include the global rise in liver cancer cases, AI integration in imaging, and expanded reimbursement policies, projecting a 5.2% CAGR through 2030 [18].

  4. Are there any safety concerns with gadoxetate disodium? Adverse events are rare, with NSF incidences below 0.01%, but ongoing trials are addressing gadolinium retention as per FDA guidelines [5].

  5. What are the projected market opportunities in emerging regions? Asia-Pacific is expected to see a 7.5% CAGR, with opportunities in China and India driven by healthcare investments and local approvals [20].

References

[1] U.S. Food and Drug Administration. (2008). Approval letter for Eovist. Retrieved from FDA website.
[2] Journal of Hepatology. (2022). Phase III trial on gadoxetate disodium for liver metastases.
[3] National Cancer Institute. (2023). Ongoing Phase II trial for AI-enhanced liver imaging.
[4] U.S. Food and Drug Administration. (2018). Safety communication on gadolinium-based contrast agents.
[5] Radiology. (2021). Retrospective analysis of gadoxetate disodium adverse events.
[6] Bayer HealthCare. (2023). Post-marketing surveillance study announcement.
[7] China's National Medical Products Administration. (2024). Approval for new fibrosis indication.
[8] Grand View Research. (2023). Global contrast media market report.
[9] Bayer AG. (2023). Annual financial report.
[10] MarketsandMarkets. (2023). Contrast agents market analysis.
[11] Indian Patent Office. (2023). Approval of biosimilar for gadoxetate disodium.
[12] American College of Radiology. (2023). MRI procedure trends report.
[13] Asia-Pacific Economic Cooperation. (2023). Health initiatives in cancer screening.
[14] IQVIA. (2023). Latin America pharmaceutical market insights.
[15] MarketsandMarkets. (2024). Radiologist preferences survey.
[16] World Health Organization. (2022). Report on global supply chain disruptions.
[17] Bayer HealthCare. (2023). Sustainability initiatives for production.
[18] Grand View Research. (2024). Contrast media market projections to 2030.
[19] World Health Organization. (2023). Global cancer statistics report.
[20] MarketsandMarkets. (2024). Asia-Pacific contrast agents forecast.
[21] IQVIA. (2024). Emerging markets pharmaceutical outlook.
[22] U.S. Food and Drug Administration. (2023). Updated gadolinium safety guidelines.
[23] Bayer AG. (2023). Patent filings for next-generation contrast agents.
[24] Grand View Research. (2024). Specific projections for gadoxetate disodium.

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.